SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LPCN

Lipocine Inc. (NASDAQ:LPCN)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.48-$0.02 (-1.33%)
 
Market cap
$16.4M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 22, 2013
Market Cap$16.39M-54.5%
Revenue (ttm)$3.74M-13.4%
Net Income-$9.33M-70.4%
EPS-$1.36-32.0%
Shares Out11.07M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume219,941
Open$1.42
Previous Close$1.50
Day's Range$1.42 - $1.53
52-Week Range$1.36 - $12.37
Beta0.50
AnalystsBuy
Price Target$4.00(+170.27%)
Earnings DateMar 8, 2027
+0.00% (1D)
No price history available.

About LPCN

Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.

Address
675 Arapeen Drive, Salt Lake City, UT, 84108, US
Market Cap
16 million
Employees
14
Industrial Classification
Biotechnology

Lipocine Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
36th Percentile Overall Score
LPCN InsiderScore:63 / 99

Lipocine Inc. scored higher than 36% of companies evaluated by InsiderBuying, and ranked 48th out of 99 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Lipocine Inc. bought $161.7K of stock across 5 purchases in the last 90 days, the largest of them $40.0K.

Stake Increase

The average purchase added about 11% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$821.49K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
0 Buy1 Hold0 SellAvg target $4.00 (+133.9%)

1 firm rating LPCN in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From LPCN’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-1.33%
5 Days
-13.45%
1 Month
+1.37%
6 Months
-34.51%
1 Year
-54.46%

$LPCN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LPCN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LPCN's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LPCN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New LPCN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LPCN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in LPCN

VTIVanguard Morningstar Total Stock Market ETF$162.01K
VXFVanguard Extended Market ETF$126.79K
DFSUDimensional - US Sustainability Core 1 ETF$7.77K
DCORU.S. Core Equity 1 Portfolio ETF Class Shares$7.67K
DFMCU.S. Micro Cap Portfolio ETF$7.56K
DFACDimensional - US Core Equity 2 ETF$7.19K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from LPCN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
63.54
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
72

News check: First Phase 3 dosing in BLOOM PPD study and Q3 2026 earnings announcement represent concrete clinical and business progress with positive implications.

Recent Insider Activity

Buys
11
Sells
0
Buy Value
$821.49K
Distinct Buyers
2

Insider Score Trend Over Time

+21.1 since Oct 1
0255075100Oct 1 — Insider Score 42.4Oct 2 — Insider Score 38.0Oct 3 — Insider Score 58.4Oct 4 — Insider Score 57.6Oct 5 — Insider Score 56.9Oct 6 — Insider Score 56.6Oct 7 — Insider Score 56.3Oct 8 — Insider Score 57.0Oct 9 — Insider Score 56.8Oct 10 — Insider Score 56.5Oct 11 — Insider Score 56.9Oct 12 — Insider Score 57.0Oct 13 — Insider Score 56.9Oct 14 — Insider Score 56.5Oct 15 — Insider Score 56.4Oct 16 — Insider Score 56.3Oct 17 — Insider Score 56.1Oct 18 — Insider Score 56.3Oct 19 — Insider Score 56.4Oct 20 — Insider Score 56.3Oct 21 — Insider Score 56.0Oct 22 — Insider Score 56.0Oct 23 — Insider Score 55.9Oct 24 — Insider Score 55.9Oct 25 — Insider Score 55.7Oct 26 — Insider Score 55.8Oct 27 — Insider Score 55.7Oct 28 — Insider Score 55.6Oct 29 — Insider Score 55.1Oct 30 — Insider Score 54.2Oct 31 — Insider Score 54.2Nov 1 — Insider Score 54.2Nov 2 — Insider Score 54.0Nov 3 — Insider Score 53.5Nov 4 — Insider Score 53.0Nov 5 — Insider Score 51.9Nov 6 — Insider Score 51.1Nov 7 — Insider Score 50.6Nov 8 — Insider Score 51.2Nov 9 — Insider Score 51.2Nov 10 — Insider Score 49.8Nov 11 — Insider Score 49.0Nov 12 — Insider Score 48.7Nov 13 — Insider Score 47.4Nov 14 — Insider Score 62.8Nov 15 — Insider Score 62.9Nov 16 — Insider Score 63.0Nov 17 — Insider Score 61.9Nov 18 — Insider Score 61.1Nov 19 — Insider Score 60.0Nov 20 — Insider Score 59.3Nov 21 — Insider Score 63.5Nov 22 — Insider Score 63.5Oct 1Oct 27Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.